Racial and Ethnic Differences in Time to Acute Reperfusion Therapy for Patients Hospitalized With Myocardial Infarction | Acute Coronary Syndromes | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.234.102. Please contact the publisher to request reinstatement.
1.
Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research.  Ann Intern Med. 2001;135:352-36611529699Google ScholarCrossref
2.
Chen J, Rathore SS, Radford MJ, Wang Y, Krumholz HM. Racial differences in the use of cardiac catheterization after acute myocardial infarction.  N Engl J Med. 2001;344:1443-144911346810Google ScholarCrossref
3.
Petersen LA, Wright SM, Peterson ED, Daley J. Impact of race on cardiac care and outcomes in veterans with acute myocardial infarction.  Med Care. 2002;40:I86-I9611789635Google Scholar
4.
Schneider EC, Leape LL, Weissman JS, Piana RN, Gatsonis C, Epstein AM. Racial differences in cardiac revascularization rates: does “overuse” explain higher rates among white patients?  Ann Intern Med. 2001;135:328-33711529696Google ScholarCrossref
5.
Agency for Healthcare Research and Quality.  National Healthcare Disparities Report: Summary. Available at: http://www.ahrq.gov/qual/nhdr03/nhdrsum03.htm. Accessed August 2, 2004
6.
Institute of Medicine.  Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press; 2003
7.
Centers for Disease Control and Prevention.  About Healthy People 2010November 20, 2003. Available at: http://www.cdc.gov/nchs/about/otheract/hpdata2010/abouthp.htm. Accessed August 2, 2004
8.
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.  Lancet. 1994;343:311-3227905143Google Scholar
9.
The GUSTO Investigators.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.  N Engl J Med. 1993;329:673-6828204123Google ScholarCrossref
10.
Goldberg RJ, Mooradd M, Gurwitz JH.  et al.  Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (the Second National Registry of Myocardial Infarction).  Am J Cardiol. 1998;82:259-2649708650Google ScholarCrossref
11.
Cannon CP, Gibson CM, Lambrew CT.  et al.  Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.  JAMA. 2000;283:2941-294710865271Google ScholarCrossref
12.
Taylor HA Jr, Canto JG, Sanderson B, Rogers WJ, Hilbe J.National Registry of Myocardial Infarction 2 Investigators.  Management and outcomes for black patients with acute myocardial infarction in the reperfusion era.  Am J Cardiol. 1998;82:1019-10239817474Google ScholarCrossref
13.
Canto JG, Taylor HA Jr, Rogers WJ, Sanderson B, Hilbe J, Barron HV. Presenting characteristics, treatment patterns, and clinical outcomes of non-black minorities in the National Registry of Myocardial Infarction 2.  Am J Cardiol. 1998;82:1013-10189817473Google ScholarCrossref
14.
Angeja BG, Gibson CM, Chin R.  et al.  Predictors of door-to-balloon delay in primary angioplasty.  Am J Cardiol. 2002;89:1156-116112008167Google ScholarCrossref
15.
Syed M, Khaja F, Rybicki BA.  et al.  Effect of delay on racial differences in thrombolysis for acute myocardial infarction.  Am Heart J. 2000;140:643-65011011340Google ScholarCrossref
16.
French WJ. Trends in acute myocardial infarction management: use of the National Registry of Myocardial Infarction in quality improvement.  Am J Cardiol. 2000;85:5B-9B11076125Google ScholarCrossref
17.
American Hospital Association.  The AnnualSurvey of Hospitals Database: Documentation for 1998 Data. Chicago, Ill: American Hospital Association; 1998
18.
Every NR, Frederick PD, Robinson M, Sugarman J, Bowlby L, Barron HV. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project.  J Am Coll Cardiol. 1999;33:1886-189410362189Google ScholarCrossref
19.
Rogers WJ, Bowlby LJ, Chandra NC.  et al.  Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction.  Circulation. 1994;90:2103-21147923698Google ScholarCrossref
20.
De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts.  Circulation. 2004;109:1223-122515007008Google ScholarCrossref
21.
Bland JM, Altman DG. The use of transformation when comparing two means.  BMJ. 1996;312:11538620137Google ScholarCrossref
22.
Bland JM, Altman DG. Transformations, means, and confidence intervals.  BMJ. 1996;312:10798616417Google ScholarCrossref
23.
King G, Tomz M, Wittenberg J. Making the most of statistical analyses: improving interpretation and presentation.  Am J Pol Sci. 2000;44:341-355Google ScholarCrossref
24.
SMG Marketing Group.  Marketing OverviewAvailable at: http://www.smg.com. Accessed 1/28/02
25.
Donner A, Klar N. Confidence interval construction for effect measures arising from cluster randomization trials.  J Clin Epidemiol. 1993;46:123-1318437028Google ScholarCrossref
26.
Leyland AH, Goldstein H. Multilevel Modelling of Health StatisticsChichester; NY: Wiley; 2001
27.
Bryk AS, Raudenbush SW. Hierarchical Linear Models: Applications and Data AnalysisNewbury Park, Calif: Sage; 1992
28.
Kaplan JB, Bennett T. Use of race and ethnicity in biomedical publication.  JAMA. 2003;289:2709-271612771118Google ScholarCrossref
29.
Kressin N, Chang B, Hendricks A, Kazis L. Agreement between administrative data and patients’ self-reports of race/ethnicity.  Am J Public Health. 2003;93:1734-173914534230Google ScholarCrossref
30.
Moscou S, Anderson MR, Kaplan JB, Valencia L. Validity of racial/ethnic classifications in medical records data: an exploratory study.  Am J Public Health. 2003;93:1084-108612835189Google ScholarCrossref
31.
Boehmer U, Kressin N, Berlowitz DR.  et al.  Self-reported vs administrative race/ethnicity data and study results.  Am J Public Health. 2002;92:1471-147212197976Google ScholarCrossref
32.
Blustein J. The reliability of racial classifications in hospital discharge abstract data.  Am J Public Health. 1994;84:1018-10218203669Google ScholarCrossref
33.
Pan CX, Glynn RJ, Mogun H, Choodnovskiy I, Avorn J. Definition of race and ethnicity in older people in Medicare and Medicaid.  J Am Geriatr Soc. 1999;47:730-73310366176Google Scholar
34.
Conigliaro J, Whittle J, Good CB.  et al.  Understanding racial variation in the use of coronary revascularization procedures: the role of clinical factors.  Arch Intern Med. 2000;160:1329-133510809037Google ScholarCrossref
35.
Ayanian JZ, Udvarhelyi IS, Gatsonis CA, Pashos CL, Epstein AM. Racial differences in the use of revascularization procedures after coronary angiography.  JAMA. 1993;269:2642-26468487447Google ScholarCrossref
36.
Canto JG, Rogers WJ, French WJ, Gore JM, Chandra NC, Barron HV. Payer status and the utilization of hospital resources in acute myocardial infarction: a report from the National Registry of Myocardial Infarction 2.  Arch Intern Med. 2000;160:817-82310737281Google ScholarCrossref
37.
King G. Institutional racism and the medical/health complex: a conceptual analysis.  Ethn Dis. 1996;6:30-468882834Google Scholar
38.
Ofili E. Ethnic disparities in cardiovascular health.  Ethn Dis. 2001;11:838-84011763309Google Scholar
39.
Collins TC, Clark JA, Petersen LA, Kressin NR. Racial differences in how patients perceive physician communication regarding cardiac testing.  Med Care. 2002;40:(suppl 1)  I27-I3411789628Google Scholar
Original Contribution
October 6, 2004

Racial and Ethnic Differences in Time to Acute Reperfusion Therapy for Patients Hospitalized With Myocardial Infarction

Author Affiliations
 

Author Affiliations: Section of Health Policy and Administration, Department of Epidemiology and Public Health (Drs Bradley and Krumholz and Ms Webster), Section of Cardiovascular Medicine (Drs McNamara and Krumholz and Mr Wang), and Robert Wood Johnson Clinical Scholars Program (Dr Krumholz), Department of Medicine at the Yale University School of Medicine, New Haven, Conn; Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven (Dr Krumholz); Flying Buttress Associates, Charlottesville, Va (Dr Herrin); Kaiser Permanente Clinical Research Unit, Denver, Colo (Dr Magid); Department of Preventive Medicine and Biometrics and the Division of Emergency Medicine at the University of Colorado Health Sciences Center, Denver (Dr Magid); Genentech Inc, South San Francisco, Calif (Dr Blaney); Division of Cardiology, Department of Medicine, Duke University, Durham, NC (Dr Peterson); Center for Cardiovascular Prevention, Research, and Education, Watson Clinic, Lakeland, Fla (Dr Canto); and Department of Emergency Medicine, Pennsylvania Hospital, Philadelphia (Dr Pollack).

JAMA. 2004;292(13):1563-1572. doi:10.1001/jama.292.13.1563
Abstract

Context Nonwhite patients experience significantly longer times to fibrinolytic therapy (door-to-drug times) and percutaneous coronary intervention (door-to-balloon times) than white patients, raising concerns of health care disparities, but the reasons for these patterns are poorly understood.

Objectives To estimate race/ethnicity differences in door-to-drug and door-to-balloon times for patients receiving primary reperfusion for ST-segment elevation myocardial infarction; to examine how sociodemographic factors, insurance status, clinical characteristics, and hospital features mediate racial/ethnic differences.

Design, Setting, and Patients Retrospective, observational study using admission and treatment data from the National Registry of Myocardial Infarction (NRMI) for a US cohort of patients with ST-segment elevation myocardial infarction or left bundle-branch block and receiving reperfusion therapy. Patients (73 032 receiving fibrinolytic therapy; 37 143 receiving primary percutaneous coronary intervention) were admitted from January 1, 1999, through December 31, 2002, to hospitals participating in NRMI 3 and 4.

Main Outcome Measure Minutes between hospital arrival and acute reperfusion therapy.

Results Door-to-drug times were significantly longer for patients identified as African American/black (41.1 minutes), Hispanic (36.1 minutes), and Asian/Pacific Islander (37.4 minutes), compared with patients identified as white (33.8 minutes) (P<.01 for all). Door-to-balloon times for patients identified as African American/black (122.3 minutes) or Hispanic (114.8 minutes) were significantly longer than for patients identified as white (103.4 minutes) (P<.001 for both). Racial/ethnic differences were still significant but were substantially reduced after accounting for differences in mean times to treatment for the hospitals in which patients were treated; significant racial/ethnic differences persisted after further adjustment for sociodemographic characteristics, insurance status, and clinical and hospital characteristics (P<.01 for all).

Conclusion A substantial portion of the racial/ethnic disparity in time to treatment was accounted for by the specific hospital to which patients were admitted, in contrast to differential treatment by race/ethnicity inside the hospital.

×